

Tuberculosis profile: Zambia

Population 2019: 18 million

Estimates of TB burden*, 2019

	Number	(Rate per 100 000 population)
Total TB incidence	59 000 (39 000-85 000)	333 (216-474)
HIV-positive TB incidence	28 000 (18 000-39 000)	154 (100-220)
MDR/RR-TB incidence**	2 700 (1 400-4 300)	15 (7.9-24)
HIV-negative TB mortality	5 900 (3 500-9 000)	33 (20-50)
HIV-positive TB mortality	9 500 (6 100-14 000)	53 (34-76)

Estimated proportion of TB cases with MDR/RR-TB*, 2019

New cases	2.4% (2.2-2.7)
Previously treated cases	18% (12-26)

Universal health coverage and social protection*


TB treatment coverage (notified/estimated incidence), 2019	61% (43-94)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2019	27% (15-41)

TB case notifications, 2019

Total new and relapse	36 150
- % tested with rapid diagnostics at time of diagnosis	45%
- % with known HIV status	98%
- % pulmonary	89%
- % bacteriologically confirmed ^	55%
- % children aged 0-14 years	7%


Incidence, New and relapse TB cases notified, HIV-positive TB incidence

(Rate per 100 000 population per year)



HIV-negative TB mortality

(Rate per 100 000 population per year)



Incidence, Notified cases by age group and sex, 2019

(Number)

- % women	32%
- % men	61%
Total cases notified	36 866

TB/HIV care in new and relapse TB patients, 2019

	Number	(%)
Patients with known HIV status who are HIV-positive	16 424	46%
- on antiretroviral therapy	15 915	97%

Drug-resistant TB care, 2019


% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases ^	97%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases ^	41%
Laboratory-confirmed cases - MDR/RR-TB ^^	515
Patients started on treatment - MDR/RR-TB ^^	500
Laboratory-confirmed cases - XDR-TB ^^	0
Patients started on treatment - XDR-TB ^^	0
MDR/RR-TB cases tested for resistance to any fluoroquinolone	156

Treatment success rate and cohort size


	Success	Cohort
New and relapse cases registered in 2018	90%	35 071
Previously treated cases, excluding relapse, registered in 2018	88%	851
HIV-positive TB cases registered in 2018	89%	20 202
MDR/RR-TB cases started on second-line treatment in 2017	76%	270
XDR-TB cases started on second-line treatment in 2017		0

TB preventive treatment, 2019


% of HIV-positive people (newly enrolled in care) on preventive treatment	49%
---	-----



Treatment success rate



Total budget



% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	13% (12-15)
---	----------------

TB financing

National TB budget, 2020 (US\$ millions)	49
- Funding source, domestic	22%
- Funding source, international	64%
- unfunded	14%

* Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.

** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

^ Calculated for pulmonary cases only

^^ Includes cases with unknown previous TB treatment history

^^^ Includes patients diagnosed before 2019 and patients who were not laboratory-confirmed

Generated 2020-10-15 by the World Health Organization (<https://www.who.int/tb/data/>)